What question did this study set out to answer?

Evaluate the safety and pilot efficacy of the platelet glycoprotein IIb/IIIa antagonist abciximab administered within 24 hours after acute ischemic stroke onset.

March 1, 2000StrokeOpen Access

Abciximab in Acute Ischemic Stroke

View Full Paper

Ask AI

Bookmark

Why the study?

Does abciximab improve functional outcome and is it safe in patients presenting within 24 hours after ischemic stroke onset?

Population

74 patients presenting within 24 hours after ischemic stroke onset

Comparison

Escalating dose of abciximab vs Placebo

Design

RCT, Randomly allocated in a ratio of 3:1, Double-blind, placebo-controlled

Follow-up

3 months

Authors

TIThe Abciximab in Ischemic Stroke InvestigatorsUniversity of Iowa

Discussion

Member takes

Implication

Supports safety of abciximab up to 24 hours post-stroke; extends evidence for glycoprotein IIb/IIIa antagonists in acute ischemic stroke.

Key Points

Evaluate the safety and pilot efficacy of the platelet glycoprotein IIb/IIIa antagonist abciximab administered within 24 hours after acute ischemic stroke onset.
Randomized, double-blind, placebo-controlled, dose-escalation trial across 38 sites assessing 74 patients presenting within 24 hours of stroke onset.
Patients received either one of four escalating doses of abciximab (N=54) or placebo (N=20) in a 3:1 allocation ratio.
Bleeding complications were monitored via head CT at 24 to 36 hours post-treatment, with clinical functional outcomes evaluated through 3 months.
No major intracranial hemorrhages occurred in either group; asymptomatic parenchymal hemorrhage appeared on scheduled CT in 4 of 54 abciximab patients (7%) versus 1 of 20 placebo patients (5%).
Six additional abciximab patients had asymptomatic hemorrhagic lesions on unscheduled scans, with 9 of 11 total hemorrhage cases observed in patients with baseline NIHSS scores >14.
At 3 months, abciximab-treated patients showed a favorable trend toward higher rates of minimal residual disability (Barthel Index ≥95 or modified Rankin Scale ≤1) compared with placebo.

Structured PICO

Does abciximab improve functional outcome and is it safe in patients presenting within 24 hours after ischemic stroke onset?

Population

74 patients presenting within 24 hours after ischemic stroke onset

Intervention

Escalating dose of abciximab (4 escalating doses studied)

Comparator

Placebo

Outcome

Safety (bleeding complications, specifically major intracranial hemorrhage) evaluated by head CT scan 24 to 36 hours after study agent administrationsafety

Abciximab appears safe when administered up to 24 hours after ischemic stroke onset and shows a trend toward improved functional outcomes.

Cite This Study

The Abciximab in Ischemic Stroke Investigators (2000) studied this question.

synapsesocial.com/papers/6a766ea3232067cbf2ec065c https://doi.org/10.1161/01.str.31.3.601

Topics

Dual antiplatelet therapy

View Full Paper

Ask AI

Bookmark

Abciximab in Acute Ischemic Stroke

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

Topics

Abciximab in Acute Ischemic Stroke

Discussion

Member takes

Implication

Key Points

Structured PICO

Cite This Study

Also Consider

Topics

Also Consider